Please login to the form below
Forxiga
This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.
Merck, Bayer get FDA priority review for heart failure drug
That includes Novartis’ Entresto (sacubitril/valsartan), which demonstrated 20% overall reduction in deaths or hospitalisations, and AstraZeneca’s Farxiga/Forxiga (dapagliflozin) which had a 26% improvement in cardiovascular death and worsening
Latest news
-
AstraZeneca’s Farxiga scores another FDA fast-track designation
Farxiga (dapagliflozin), sold under the brand name Forxiga in the UK, has scored a fast-track designation and is aiming for approval to reduce the risk of hospitalisation for heart failure
-
Merck, Bayer flesh out vericiguat heart failure data at ACC
Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also
-
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes
from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin).
-
AZ’s Farxiga gets heart failure prevention okay from FDA
The FDA approval comes shortly after the same indication was approved in Europe (where the drug is sold as Forxiga), and should add further momentum to what is already strong sales
-
Tecentriq’s triple negative breast cancer use among key CHMP nods
AstraZeneca’s Forxiga gained European marketing authorisation to include use in patients with type 2 diabetes at risk of cardiovascular (CV) events. ... This follows results from its DECLARE-TIMI 58 trial, which compared the effect of Forxiga with
More from news
Approximately 16 fully matching, plus 48 partially matching documents found.
Latest Intelligence
-
Leading AstraZeneca’s return to growth in Europe
receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s Forxiga (dapagliflozin).
-
The evolution of real-world studies
AstraZeneca is putting its confidence in UK infrastructure to the test in a pragmatic trial designed to compare the effectiveness of diabetes drug Forxiga to the standard of care.
-
Biopharma's Future: Made in China
targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.
-
Market dynamics, marketing and analytics
Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.
-
Interview: Christopher Boulton, AstraZeneca
Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
